2 predictions for Eli Lilly in 2026

Can anything stop this high-flying drugmaker?
Healio

Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...
TipRanks on MSN

Eli Lilly’s retatrutide study: A new hope for CKD treatment?

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...
StockStory.org on MSN

Why Eli Lilly (LLY) stock is trading up today

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the ...

Eli Lilly just delivered fantastic news to investors

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...
Fierce Biotech

Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...